Pharmedic (PMC) Stock Drops 10% on Nationwide Eye Drop Recall

Overview

Pharmedic (HNX: PMC) faced a sharp stock decline of nearly 10% on May 15, 2026, following a nationwide recall of its eye drop product due to quality non-compliance. The recall, initiated by the Lam Dong Department of Health on May 14, targets a single batch of Natri clorid 0.9% ophthalmic solution that failed the clarity specification. The incident highlights regulatory risks for pharmaceutical manufacturers in Vietnam and adds to PMC’s ongoing price correction from its 2025 highs.

Key Facts

• The recall covers one batch (lot number 10370725) of Natri clorid 0.9% eye drops, produced on July 14, 2025, with expiry January 14, 2028.
• The product failed the clarity test, classified as a Level 3 violation under Vietnamese drug regulations.
• PMC stock fell 9.5% to VND 126,300 per share by 13:15 on May 15, 2026, with low volume of about 700 shares traded.
• The recall order requires all distributors and healthcare facilities to stop using the batch and return it by May 29, 2026.
• In Q1 2026, PMC reported net profit of nearly VND 23 billion, slightly up year-on-year.
• PMC’s annual net profit has been stable around VND 80-84 billion in recent years.
• The stock has been in a downtrend from its December 2025 peak of over VND 180,000, despite stable earnings.

What Happened

On May 14, 2026, the Lam Dong Department of Health issued a nationwide recall for a batch of Pharmedic’s Natri clorid 0.9% eye drops after the product failed quality testing for clarity. The recall was directed by the Drug Administration of Vietnam and applies to the single batch with registration number 893100060724. The violation is classified as Level 3, the most serious category, indicating potential risk to patient safety.

The company, CTCP Duoc pham Duoc lieu Pharmedic (PMC), is required to coordinate the recall and report results by May 29, 2026. The stock reacted negatively the next day, dropping nearly 10% on thin volume. The incident comes amid a broader price correction for PMC, which has seen its share price fall from a peak of over VND 180,000 in December 2025 to current levels, despite relatively stable financial performance.

Market Context

PMC shares closed at VND 139,500 on May 14, 2026, with negligible volume of 1,600 shares. The stock has been in a sustained downtrend since late 2025, characterized by very low average trading volume of around 2,000 shares. The recall news triggered a sharp intraday drop, but the low liquidity suggests limited institutional interest. The pharmaceutical sector on HNX has been relatively quiet, with PMC’s valuation still elevated compared to historical levels. The company’s stable earnings (VND 80-84 billion net profit annually) have not prevented the price correction, indicating that the earlier rally may have been speculative.

Strategic Significance

For long-term investors, the recall event underscores regulatory and operational risks inherent in pharmaceutical manufacturing. While the financial impact of a single batch recall is likely minimal for PMC given its scale, the reputational damage and potential for further regulatory scrutiny could weigh on sentiment. The company’s stable earnings profile and niche in herbal and generic drugs provide a defensive buffer, but the stock’s low liquidity and high volatility make it a challenging holding. The recall may also prompt investors to reassess quality control processes at PMC and its peers.

What to Watch

• Completion of the recall process and any additional batches flagged by regulators.
• PMC’s Q2 2026 earnings report for any provisions or charges related to the recall.
• Trading volume and price action to see if the stock stabilizes or continues to decline.
• Any statements from PMC management regarding corrective actions or quality improvements.
• Broader regulatory trends in Vietnam’s pharmaceutical sector, especially enforcement of GMP standards.